ArticleBiomarkers in medicine2025
The systemic inflammatory response index (SIRI) as a prognostic factor for long-term survival in patients with pancreatic cancer.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPancreatic cancer has a very poor prognosis and is a leading cause of cancer-related deaths. Our aim is to investigate the presence of novel prognostic markers in pancreatic cancer that are easy to calculate, inexpensive, non-invasive, and do not cause a loss of time.
methodsA total of 164 patients were included in the study. The demographic and clinical characteristics, laboratory findings, and radiological data of the patients were retrospectively reviewed using hospital records.
resultsOf the patients, 112 (68.3%) were male, and the mean age of all patients was 63.29 ± 12.5 years. The one-,two-,and five-year survival rates of the patients were determined to be 43.9% (
conclusionWe found that SIRI is a stronger prognostic factor than the NLR, PIV, and SII indices in predicting survival in pancreatic cancer. Monitoring SIRI in pancreatic cancer may provide insight into the status of the local immune response and systemic inflammation, and help in estimating patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.